According to the FDA approval listing, the FDA approved Tauklarify (florquinitau F 18) on August 13, 2026 for brain PET in adults with cognitive impairment evaluated for Alzheimer's disease FDA approval listing. People with mild cognitive impairment can bring focused questions about amyloid status, result meaning, scan availability, and treatment-trial relevance to a clinician. Tau PET imaging is a brain scan that highlights tau tangles, twisted protein deposits linked to Alzheimer's disease. Mild cognitive impairment means measurable memory or thinking changes that do not yet prevent daily activities.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official guidance from Neurologylive — Use this primary source to verify the official guidance.
Table of Contents
- What does a Tauklarify scan add?
- How well was it tested in people like you?
- What should you ask about your diagnosis?
- What happens on scan day?
- Could results affect treatment or trial choices?
What does a Tauklarify scan add?
Tauklarify was studied earlier as MK-6240, an F-18 labeled tracer for Alzheimer's evaluation. It joins Lilly's Tauvid (flortaucipir, approved in 2020) as an FDA-approved tau tracer, according to the Society of Nuclear Medicine and Molecular Imaging society update. The tracer binds tau tangles and can complement amyloid PET. Amyloid PET shows a different Alzheimer's protein.
Together, the two scans give a fuller biological picture. For mild cognitive impairment, that pairing matters. Memory symptoms have many causes. Tau and amyloid results help a clinician judge whether Alzheimer's pathology fits the symptoms.
How well was it tested in people like you?
The pivotal reading studies used 617 scans, NeurologyLive reported, including 157 people with mild cognitive impairment, 152 with mild Alzheimer's dementia, and 308 without impairment NeurologyLive report. Five independent blinded readers rated each scan in each study. That design reduces bias from knowing the diagnosis. Positive agreement ranged from 68% to 88%.
Negative agreement ranged from 93% to 99%, with strong agreement among readers. In plain terms, negative reads were more consistent than positive reads. Performance was mainly validated by comparing amyloid-negative unimpaired people with amyloid-positive impaired people. Accuracy may be lower earlier in disease. Safety and effectiveness are not established for non-Alzheimer's tauopathies.
What should you ask about your diagnosis?
Ask whether your amyloid status is known or still needed. Tau alone does not diagnose Alzheimer's disease. Your clinician combines scans with history, exams, cognitive testing, and sometimes spinal fluid or blood markers. Ask what each result would change.
A useful prompt is: if positive, what diagnosis follows, and if negative, what else explains my symptoms. Bring a list of medicines, smoking status, and recent infections or brain injuries. Labeling warns that a negative scan does not necessarily exclude tau pathology. A positive scan does not necessarily confirm tissue disease. Ask what added evaluation is planned when uncertainty remains.
What happens on scan day?
The scan uses about 185 MBq (5 mCi) given intravenously, Pharmacy Times reported Pharmacy Times summary. In 1,734 people, the most common side effects were headache (0.7%) and nausea (0.2%). Ask about radiation precautions, hydration, and voiding before and after the tracer.
Ask whether you should avoid smoking and CYP1A2 inducers for seven days before imaging. If breastfeeding, ask about pausing for four hours after injection. Confirm logistics in one call. Useful checks are:.
- Is the tracer stocked at this center or referred elsewhere
- How long is the visit, including uptake and scan time
- Who explains the read, and when
- What records to bring, including prior amyloid PET and MRI
Could results affect treatment or trial choices?
Some Alzheimer's treatments and trials require amyloid confirmation. Others consider tau burden, disease stage, or coexisting conditions. Ask whether a tau result makes any therapy or study more or less relevant for you. Ask what threshold the clinic uses, if any, for positive versus uncertain.
Readers can disagree, especially near the cut point. Ask whether a second read, quantitative measure, or repeat clinical follow-up is used. Bring a decision partner when possible. Ask for written results, the visual read, and the next step if symptoms progress despite a negative scan. Keep asking until the plan names diagnosis, monitoring interval, safety steps, and support resources.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
